31 August 2022>: Clinical Research
Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4–6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo
Blerim Myftiu 12ABCDEFG* , Zylfije Hundozi 12ACDF , Faton Sermaxhaj 3ABD , Afrim Blyta 1ACDF , Nexhmedin Shala 12CD , Fisnik Jashari 12C , Hasime Qorraj Bytyqi 4CDF , Ekrem Hyseni 3BC , Ilir Kurtishi 3BCDOI: 10.12659/MSM.937856
Med Sci Monit 2022; 28:e937856
Table 2 Chemotherapy protocols.
Treatment regimen | Number | Age (Mean±SD) |
---|---|---|
Platinum only | 2 | 61±1.4 |
Platinum + Taxane | 20 | 62.5±10.7 |
Platinum + Antimetabolites | 53 | 61.45±8.4 |
Platinum + Taxane + Doxorubicin | 1 | 55 |
Platinum + Taxane + Antimetabolites | 1 | 58 |
Platinum + Doxorubicin + Antimetabolites | 1 | 50 |
Platinum + Dacarbazine | 1 | 55 |
Platinum + Etoposide | 4 | 44.5±19.3 |
Taxane + Antimetabolites | 6 | 58.6±8.0 |
Taxane + Doxorubicin | 2 | 70±7.0 |
Taxane + Doxorubicin + Alkylating | 20 | 55±13.1 |
Irinotecan + Antimetabolites | 3 | 65.6±4.6 |
Alkilating + Doxorubicin | 4 | 57.7±13.4 |
Doxorubicin + Vinblastin + Dacarbazine + Bleomycin | 1 | 26 |
Taxane + Antimetabolites + Etoposide | 1 | 51 |
SD – standard deviation. |